CN114650815A - 癌症治疗的方法及组成物 - Google Patents

癌症治疗的方法及组成物 Download PDF

Info

Publication number
CN114650815A
CN114650815A CN202080076324.7A CN202080076324A CN114650815A CN 114650815 A CN114650815 A CN 114650815A CN 202080076324 A CN202080076324 A CN 202080076324A CN 114650815 A CN114650815 A CN 114650815A
Authority
CN
China
Prior art keywords
compound
chemotherapeutic agents
formula
plag
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080076324.7A
Other languages
English (en)
Chinese (zh)
Inventor
孙基永
J·W·金
尹宣映
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enzychem Lifesciences Corp
Original Assignee
Enzychem Lifesciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzychem Lifesciences Corp filed Critical Enzychem Lifesciences Corp
Publication of CN114650815A publication Critical patent/CN114650815A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202080076324.7A 2019-10-28 2020-10-28 癌症治疗的方法及组成物 Pending CN114650815A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962926963P 2019-10-28 2019-10-28
US62/926,963 2019-10-28
PCT/IB2020/060104 WO2021084441A2 (en) 2019-10-28 2020-10-28 Methods and compositions for treatment of cancer

Publications (1)

Publication Number Publication Date
CN114650815A true CN114650815A (zh) 2022-06-21

Family

ID=75714907

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080076324.7A Pending CN114650815A (zh) 2019-10-28 2020-10-28 癌症治疗的方法及组成物

Country Status (6)

Country Link
US (1) US20220370397A1 (https=)
EP (1) EP4051260A4 (https=)
JP (1) JP2022553421A (https=)
KR (1) KR20220114532A (https=)
CN (1) CN114650815A (https=)
WO (1) WO2021084441A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020144538A1 (en) * 2019-01-07 2020-07-16 Enzychem Lifesciences Corporation Compositions and methods for modulating an inflammatory response
US20220125882A1 (en) * 2019-01-16 2022-04-28 Enzychem Lifesciences Corporation Methods and compositions for treatment of cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1946392A (zh) * 2004-04-24 2007-04-11 金尚姬 含有单乙酰基二酰基甘油衍生物的免疫调节剂、抗癌剂和健康食品
CN106535887A (zh) * 2014-05-15 2017-03-22 株式会社Enzychem生命科学 治疗白细胞减少症和血小板减少症的方法
CN109476748A (zh) * 2016-08-08 2019-03-15 豪夫迈·罗氏有限公司 用于癌症的治疗和诊断方法
CA3084594A1 (en) * 2017-11-30 2019-06-06 Enzychem Lifesciences Corporation Compositions for prevention or treatment of acute radiation syndrome
CN113613670A (zh) * 2019-01-16 2021-11-05 Enzychem生命科学株式会社 治疗癌症的方法和组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100283010B1 (ko) * 1997-11-20 2001-04-02 전길자 녹용 추출물을 함유하는 조혈모세포 및 혈소판 전구세포 증식촉진용 조성물
CA2562897C (en) * 2004-04-24 2011-03-15 Sang-Hee Kim Immunomodulating agent, anti-cancer agent and health food containing monoacetyldiacylglycerol derivatives
EP3037092B1 (en) * 2013-08-19 2020-01-01 Enzychem Lifesciences Corporation Composition containing monoacetyldiglyceride compound as active ingredient for inhibiting blood cancer
AU2016226157B2 (en) * 2015-03-04 2022-01-27 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and eribulin for treating cancer
EP3400218A4 (en) * 2016-01-08 2019-09-18 Euclises Pharmaceuticals, Inc. COMBINATION OF A CHROME CONNECTION AND A SECOND ACTIVE SUBSTANCE
JP7194022B2 (ja) * 2016-05-20 2022-12-21 イーライ リリー アンド カンパニー Ｎｏｔｃｈ阻害剤とＰＤ－１またはＰＤ－Ｌ１阻害剤との併用療法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1946392A (zh) * 2004-04-24 2007-04-11 金尚姬 含有单乙酰基二酰基甘油衍生物的免疫调节剂、抗癌剂和健康食品
CN106535887A (zh) * 2014-05-15 2017-03-22 株式会社Enzychem生命科学 治疗白细胞减少症和血小板减少症的方法
CN109476748A (zh) * 2016-08-08 2019-03-15 豪夫迈·罗氏有限公司 用于癌症的治疗和诊断方法
CA3084594A1 (en) * 2017-11-30 2019-06-06 Enzychem Lifesciences Corporation Compositions for prevention or treatment of acute radiation syndrome
CN113613670A (zh) * 2019-01-16 2021-11-05 Enzychem生命科学株式会社 治疗癌症的方法和组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JINSEON JEONG ET AL: "1-Palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol (PLAG) attenuates gemcitabine-induced neutrophil extravasation", 《CELL & BIOSCIENCE》, vol. 9, pages 1 - 15, XP055819793, DOI: 10.1186/s13578-018-0266-7 *
MYUNG-HWAN KIM ET AL: "EC-18, a Synthetic Monoacetyldiacylglyceride, Inhibits Hematogenous Metastasis of KIGB-5 Biliary Cancer Cell in Hamster Model", 《JOURNAL OF KOREAN MEDICAL SCIENCE》, vol. 24, pages 474 - 480, XP055321285, DOI: 10.3346/jkms.2009.24.3.474 *

Also Published As

Publication number Publication date
US20220370397A1 (en) 2022-11-24
KR20220114532A (ko) 2022-08-17
EP4051260A2 (en) 2022-09-07
WO2021084441A3 (en) 2021-06-10
JP2022553421A (ja) 2022-12-22
WO2021084441A2 (en) 2021-05-06
EP4051260A4 (en) 2023-12-06

Similar Documents

Publication Publication Date Title
US20210161928A1 (en) Cancer therapy via a combination of epigenetic modulation and immune modulation
US8003105B2 (en) Method of treating cancer by co-administration of anticancer agents
US10342815B2 (en) GLA monotherapy for use in cancer treatment
RU2391101C2 (ru) Комбинированное применение эктеинасцидина-743 и содержащих платину противоопухолевых соединений
WO2014142220A1 (ja) 抗腫瘍剤
US20220088042A1 (en) Combination therapy including sapc-dops for the treatment of pancreatic cancer
CN114650815A (zh) 癌症治疗的方法及组成物
US9040500B2 (en) Method for treating hematopoietic neoplasms
KR20180014834A (ko) 카보플라틴을 함유하는 조성물 및 용도
WO2023209625A1 (en) Compositions and methods for treatment of cancer
EP2441452B1 (en) Pharmaceutical composition and use of the pharmaceutical composition for the treatment, prophylaxis or prevention of neoplastic diseases in humans and animals
de Souza Neto et al. Analysis of scientific evidence on the effectiveness of immunomodulation in cancer: a systematic review
US20050234009A1 (en) Method of treating solid tumors and leukemias using combination therapy of vitamin D and anti-metabolic nucleoside analogs
EP4687900A2 (en) Combination treatment for ovarian cancer
US20250041286A1 (en) Cancer treatment using ketotifen in combination with a checkpoint inhibitor
JP7534581B2 (ja) 癌免疫増強剤、及びそれを含有する増強抗癌剤
US20210100859A1 (en) Herpes simplex virus (hsv) anticancer therapies
Nishihori et al. Safety and Efficacy of Letetresgene Autoleucel (lete-cel; GSK3377794) Alone or in Combination with Pembrolizumab in Relapsed and Refractory Multiple Myeloma
US20220002723A1 (en) Methods for the treatment of small round cell tumors
WO2023210042A1 (ja) Ｉｌ－３４を発現する腫瘍を治療および／または予防するための医薬
WO2021092190A1 (en) Combination therapy for cancer
EP1562610A1 (en) Combination therapy with gemcitabine and zd6126

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination